病毒学报

参考文献

[1]Shepard C W,Finelli L,Alter M J.Global epidemiology of hepatitis C virus infection[J].Lancet Infect Dis,2005,5(9):558-567.

[2]Afdhal N H.The natural history of hepatitis C[J].Semin Liver Dis,2004,24(Suppl.2):3-8.

[3]McHutchison J G,Lawitz E J,Shiffman M L,Muir A J,Galler G W,McCone J,Nyberg L M,Lee W M,Ghalib R H,Schiff E R,Galati J S,Bacon B R,Davis M N,Mukhopadhyay P,Koury K,Noviello S,Pedicone L D,Brass C A,Albrecht J K,Sulkowski M S.IDEAL Study Team.Peginterferon alfa-2bor alfa-2awith ribavirin for treatment of hepatitis C infection[J].N Engl J Med,2009,361:580-593.

[4]Jacobson I M,McHutchison J G,Dusheiko G,Di Bisceglie A M,Reddy K R,Bzowej N H,Marcellin P,Muir A J,Ferenci P,Flisiak R,George J,Rizzetto M,Shouval D,Sola R,Terg R A,Yoshida E M,Adda N,Bengtsson L,Sankoh A J,Kieffer T L,George S,Kauffman R S,Zeuzem S.ADVANCE Study Team.Telaprevir for previously untreated chronic hepatitis C virus infection[J].N Engl J Med,2011,364:2405-2416.

[5]Poordad F,McCone J Jr,Bacon B R,Bruno S,Manns M P,Sulkowski M S,Jacobson I M,Reddy K R,Goodman Z D,Boparai N,DiNubile M J,Sniukiene V,Brass C A,Albrecht J K,Bronowicki J P.SPRINT-2Investigators.Boceprevir for untreated chronic HCV genotype 1infection[J].N Engl J Med,2011,364:1195-1206.

[6]Torresi J,Johnson D,Wedemeyer H.Progress in the development of preventive and therapeutic vaccines for hepatitis C virus[J].J Heptol,2011,54:1273-1285.

[7]Bukh J,Miller R H,Purcell R H.Genetic heterogeneity of hepatitis C virus:quasispecies and genotypes[J].Semin Liver Dis,1995,15:41-63.

[8]Barnes E,Folgori A,Capone S,Swadling L,Aston S,Kurioka A,Meyer J,Huddart R,Smith K,Townsend R,Brown A,Antrobus R,Ammendola V,Naddeo M,O′Hara G,Willberg C,Harrison A,Grazioli F,Esposito M L,Siani L,Traboni C,Oo Y,Adams D,Hill A,Colloca S,Nicosia A,Cortese R,Klenerman P.Novel adenovirusbased vaccines induce broad and sustained T cell responses to HCV in man[J].Sci Transl Med,2012,4;4(115):115ra1.

[9]Lazdina U,Hultgren C,Frelin L,Chen M,Lodin K,Weiland O,Leroux-Roels G,Quiroga JA,Peterson D L,Milich D R,Sllberg M.Humoral and CD4(+)T helper(Th)cell responses to the hepatitis C virus nonstructural3(NS3)protein:NS3primes Th1-like responses more effectively asa DNA-based immunogen than as a recombinant protein[J].J Gen Virol,2001,82:1299-1308.

[10]Diepolder H M,Gerlach J T,Zachoval R,Hoffmann R M,Jung M C,Wierenga E A,Scholz S,Santantonio T,Houghton M,Southwood S,Sette A,Pape G R.Immunodominant CD4+T-cell epitope within nonstructural protein 3in acute hepatitis C virus infection[J].J Viro1,1997,71:6011-6019.

[11]Krishnadas D K,Ahn J S,Han J,Kumar R,Agrawal B.Immunomodulation by hepatitis C virus-derived proteins:targeting human dendritic cells by multiple mechanisms[J].Int Immunol,2010,22(6):491-502.

[12]Krishnadas D K,Li W,Kumar R,Tyrrell L J,Agrawal B.In vitro activation and differentiation of naive CD4+and CD8+T cells into HCV core-and NS3-specific armed effector cell:a new role for CD4+T cells[J].Cell Immunol,2009,259(2):141-149.

[13]Haller A A,Lauer G M,King T H,Kemmler C,Fiolkoski V,Lu Y,Bellgrau D,Rodell T C,Apelian D,Franzusoff A,Duke R C.Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3and Core proteins[J].Vaccine,2007,25(8):1452-1463.

[14]Sarobe P,Lasarte J J,Zabaleta A,Arribillaga L,Arina A,Melero I,Borrás-Cuesta F,Prieto J.Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses[J].J Virol,2003,77:10862-10871.

[15]Liu Y,Zhou W,You C,Zheng H,You H,Liu H,Zhang D,Luo R,Kay H H,Hermonat P L.An autoimmune domain-reduced HCV core gene remains effective in stimulating anti-core cytotoxic T lymphocyte activity[J].Vaccine,2006,24:1615-1624.

[16]Andersson H A,Singh R A,Barry M A.Activation of refractory T cell responses against hepatitis C virus core protein by ablation of interfering hydrophobic domains[J].Mol Ther,2006,13(2):338-346.

[17]Zimmermann M,Flechsig C,La Monica N,Tripodi M,Adler G,Dikopoulos N.Hepatitis C virus core protein impairs in vitro priming of specific T cell responses by dendritic cells and hepatocytes[J].J Hepatol,2008,48(1):51-60.

[18]Alvarez-Obregón J C,Dueas-Carrera S,Valenzuela C,Grillo J M.A truncated HCV core protein elicits a potent immune response with a strong participation of cellular immunity components in mice[J].Vaccine,2001,19(28-29):3940-3946.

[19]Hosseini S Y,Sabahi F,Moazzeni S M,Modarressi M H,Saberi Firoozi M,Ravanshad M.Construction and preparation of three recombinant adenoviruses expressing truncated NS3and core genes of hepatitis C virus for vaccine purposes[J/OL].Hepat Mon,2012,12(8):e6130.

[20]Habersetzer F,Baumert T F,Stoll-Keller F.GI-5005,a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection[J].Curr Opin Mol Ther,2009,11(4):456-462.

[21]Li W,Krishnadas D K,Li J,Tyrrell D L,Agrawal B.Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3or core by autologous dendritic cells expressing hepatitis C virus antigens:potential for vaccine and immunotherapy[J].J Immunol,2006,176(10):6065-6075.

[22]Guan J,Wen B,Deng Y,Zhang K,Chen H,Wu X,Ruan L,Tan W.Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes[J].Virol J,2011,8:506.

[23]Deng Y,Guan J,Wen B,Zhu N,Chen H,Song J,Yang Y,Wang Y,Tan W.Induction of broadly neutralising HCV antibodies in mice by integration-deficient lentiviral vector-based pseudotyped particles[J/OL].PLoS One,2013,8(4):e62684.

[24]Ng P,Parks R J,Cummings D T,Evelegh C M,Graham F L.An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method[J].Hum Gene Ther,2000,11:693-699.

[25]Bowen D G,Walker C M.Mutational escape from CD8+T cell immunity:HCV evolution,from chimpanzees to man[J].J Exp Med,2005,201(11):1709-1714.

[26]Uebelhoer L,Han H,Callendret B,Mateu G,Shoukry N H,Hanson H L,Rice C M,Walker C M,Grakoui A.Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness[J/OL].PLoS Pathog,2008,4(9):e1000143.

[27]von Hahn T,Yoon J C,Alter H,Rice C M,Rehermann B,Balfe P,McKeating J A.Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo[J].Gastroenterology,2007,32(2):667-678.

[28]Bowen D G,Walker C M.Adaptive immune responses in acute and chronic hepatitis C virus infection[J].Nature,2005,436(7053):946-952.

[29]Lauer G M.Immune responses to hepatitis C virus(HCV)infection and the prospects for an effective HCV vaccine or immunotherapies[J].J Infect Dis,2013,207Suppl 1:S7-S12.

[30]Krishnadas D K,Li W,Kumar R,Tyrrell D L,Agrawal B.HCV-core and NS3antigens play disparate role in inducing regulatory or effector T cells in vivo:Implications for viral persistence or clearance[J].Vaccine,2010,28(9):2104-2114.

[31]El-Gogo S,Staib C,Lasarte J J,Sutter G,Adler H.Protective vaccination with hepatitis C virus NS3but not core antigen in a novel mouse challenge model[J].J Gene Med,2008,10(2):177-186.

[32]Chen A,Ahlén G,Brenndrfer E D,Brass A,Holmstrm F,Chen M,Sderholm J,Milich D R,Frelin L,Sllberg M.Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural3/4A-specific T cells during therapeutic vaccination[J].J Immunol,2011,186(9):5107-5118.

[33]Schulze zur Wiesch J,Lauer G M,Day C L,Kim A Y,Ouchi K,Duncan J E,Wurcel A G,Timm J,Jones A M,Mothe B,Allen T M,McGovern B,Lewis-Ximenez L,Sidney J,Sette A,Chung R T,Walker B D.Broad repertoire of the CD4+Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes[J].J Immunol,2005,175(6):3603-3613.

[34]Stoll-Keller F,Barth H,Fafi-Kremer S,Zeisel M B,Baumert T F.Development of hepatitis C virus vaccines:challenges and progress[J].Expert Rev Vaccines,2009,8(3):333-345.

[35]Dustin L B,Rice C M.Flying under the radar:the immunobiology of hepatitis C[J].Annu Rev Immunol,2007,5:71-99.

[36]Grakoui A,Shoukry N H,Woollard D J,Han J H,Hanson H L,Ghrayeb J,Murthy K K,Rice C M,Walker C M.HCV persistence and immune evasion in the absence of memory T cell help[J].Science,2003,02:59-62.

[37]Kristensen N N,Christensen J P,Thomsen A R.High numbers of IL-2-producing CD8+T cells during viral infection:correlation with stable memory development[J].J Gen Virol,2002,83:2123-2133.

[38]Wherry E J,Ahmed R.Memory CD8T-cell differentiation during viral infection[J].J Virol,2004,78:5535-5545.

[39]Habersetzer F,Honnet G,Bain C,Maynard-Muet M,Leroy V,Zarski J P,Feray C,Baumert T F,Bronowicki J P,Doffol M,Trépo C,Agathon D,Toh M L,Baudin M,Bonnefoy J Y,Limacher J M,InchauspéG.A poxvirus vaccine is safe,induces T-cell responses,and decreases viral load in patients with chronic hepatitis C[J].Gastroenterology,2011,141:890-899.

[40]Verstrepen B E,Verschoor E J,Fagrouch Z C,Mooij P,de Groot N G,Bontrop R E,Bogers W M,Heeney J L,Koopman G.Strong vaccine-induced CD8 T-cell responses have cytolytic function in a chimpanzee clearing HCV infection[J/OL].PLoS One,2014,9(4):e95103.